UK plans to make pseudoephedrine script-only

The MHRA, the equivalent of the Therapeutic Goods Administration in Australia, has recommended rescheduling pseudoephedrine to prescription-only within 24 months unless the risk of diversion is contained.

The move has prompted Australian pharmacy's peak bodies to remind pharmacists to remain vigilant, support Project Stop and be security conscious.

"Whilst we are perceived to be doing a great job, methylamphetamine is still high on the national agenda," said Kos Sclavos, national president of the Pharmacy Guild of Australia.

"If the UK has been given notice, we have to realise that the issue won't go away here, even in light of our investment in protocols and quality procedures such as Project Stop," Mr Sclavos said.

Pharmaceutical Society of Australia national president, Brian Grogan, said he also believed Australia needed to remain on top of pseudoephedrine diversion.

"We cannot return to the old system and cannot afford to be complacent. We can't afford to say 'we've reduced pack sizes, minimised our stock holding, tightened restrictions and introduced the Guild's Project Stop program, so the problem is solved'.

"A lot of countries are surprised at how proactive Australia has been in dealing with the issue and pharmacy should be commended.

"However, the war is not over; it is a continuing battle and we must remain vigilant in how we manage it," Mr Grogan said.